Although many neoplasms display some resistance to Apo2L/TRAIL in clinical trials, a growing body of data demonstrates that Apo2L/TRAIL can selectively kill cancer cells without harming normal cells, which could alleviate many side effects of conventional chemotherapy. Here, TNFSF10 is linked to neoplasm.